M. Hanafiah, K. Groeger, J. Flaxman, A. D. Wiersma, and S. T. , Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence, Hepatology, vol.57, issue.4, p.23172780, 2013.

, WHO. Global hepatitis report, 2017. 2017:83. Epub, 2017.

T. J. Liang and M. G. Ghany, Current and future therapies for hepatitis C virus infection, N Engl J Med, vol.368, issue.20, pp.1907-1924, 2013.
DOI : 10.1056/nejmra1213651
URL : http://europepmc.org/articles/pmc3893124?pdf=render

J. Bukh, The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control, J Hepatol, vol.65, issue.1, p.27641985, 2016.

B. R. Edlin, Access to treatment for hepatitis C virus infection: time to put patients first, Lancet Infect Dis, vol.16, issue.9, p.27421993, 2016.

J. Grebely, K. Page, R. Sacks-davis, M. S. Van-der-loeff, T. M. Rice et al., The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection, Hepatology, vol.59, issue.1, p.3972017, 2014.

J. M. Pestka, M. B. Zeisel, E. Blaser, P. Schurmann, B. Bartosch et al., Rapid induction of virusneutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proc Natl Acad Sci, vol.104, issue.14, p.1851610, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00395910

W. O. Osburn, A. E. Snider, B. L. Wells, R. Latanich, J. R. Bailey et al., Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses, Hepatology, vol.59, issue.6, p.4043926, 2014.

F. Luciani, N. A. Bretana, S. Teutsch, J. Amin, L. Topp et al., A prospective study of hepatitis C incidence in Australian prisoners, Addiction, vol.109, issue.10, p.24916002, 2014.

D. Ge, J. Fellay, A. J. Thompson, J. S. Simon, K. V. Shianna et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.461, issue.7262, pp.399-401, 2009.

Z. Y. Keck, J. Xia, Y. Wang, W. Wang, T. Krey et al., Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate, PLoS Pathog, vol.8, issue.4, p.3325216, 2012.

Z. Keck, W. Wang, Y. Wang, P. Lau, T. H. Carlsen et al., Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein, J Virol, vol.87, issue.1, p.3536422, 2013.

Z. Y. Keck, T. K. Li, J. Xia, M. Gal-tanamy, O. Olson et al., Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies, J Virol, vol.82, issue.12, p.18400849, 2008.

J. Prentoe and J. Bukh, In Vitro Neutralization Assay Using Cultured Hepatitis C Virus, Methods Mol Biol, vol.1911, p.30593643, 2019.

B. D. Lindenbach, M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen et al., Complete replication of hepatitis C virus in cell culture, Science, vol.309, issue.5734, p.15947137, 2005.

T. K. Scheel, J. M. Gottwein, T. B. Jensen, J. C. Prentoe, A. M. Hoegh et al., Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization, Proc Natl Acad Sci, vol.105, issue.3, p.2242719, 2008.

J. M. Gottwein, T. K. Scheel, T. B. Jensen, J. B. Lademann, J. C. Prentoe et al., Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs, Hepatology, vol.49, issue.2, p.19148942, 2009.

T. K. Scheel, J. M. Gottwein, T. H. Carlsen, Y. P. Li, T. B. Jensen et al., Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations, J Virol, vol.85, issue.6, p.3067958, 2011.

T. B. Jensen, J. M. Gottwein, T. K. Scheel, A. M. Hoegh, J. Eugen-olsen et al., Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection, J Infect Dis, vol.198, issue.12, pp.1756-65, 2008.

S. Ramirez and J. Bukh, Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies, Antiviral Res, vol.158, p.30059723, 2018.

J. Prentoe, T. B. Jensen, P. Meuleman, S. B. Serre, T. K. Scheel et al., Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization, J Virol, vol.85, issue.5, p.3067759, 2011.

J. Pedersen, T. H. Carlsen, J. Prentoe, S. Ramirez, T. B. Jensen et al., Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies, Hepatology, vol.58, issue.5, p.4415732, 2013.

J. Prentoe, R. Velazquez-moctezuma, S. K. Foung, M. Law, and J. Bukh, Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity, Hepatology, vol.64, issue.6, p.5115964, 2016.

J. Prentoe and J. Bukh, Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry, Front Immunol, vol.9, p.6170631, 2018.

R. Velazquez-moctezuma, M. Law, J. Bukh, and J. Prentoe, Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A, PLoS Pathog, vol.13, issue.2, p.5358973, 2017.

J. K. Ball, A. W. Tarr, and J. A. Mckeating, The past, present and future of neutralizing antibodies for hepatitis C virus, Antiviral Res, vol.105, issue.100, p.4034163, 2014.

Z. Y. Keck, A. Op-de-beeck, K. G. Hadlock, J. Xia, T. K. Li et al., Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions, J Virol, vol.78, issue.17, p.15308717, 2004.

M. L. Keck, F. Wrensch, B. G. Pierce, T. F. Baumert, and S. Foung, Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine, Front Immunol, vol.9, p.5991293, 2018.

B. G. Pierce, Z. Y. Keck, P. Lau, C. Fauvelle, R. Gowthaman et al., Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design, Proc Natl Acad Sci, p.5111724, 2016.

R. Gopal, K. Jackson, N. Tzarum, L. Kong, A. Ettenger et al., Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis, PLoS Pathog, vol.13, issue.12, p.5749897, 2017.

R. Velazquez-moctezuma, A. Galli, M. Law, J. Bukh, and J. Prentoe, Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms, J Virol, vol.93, issue.4, p.6364003, 2019.

E. Giang, M. Dorner, J. C. Prentoe, M. Dreux, M. J. Evans et al., Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus, Proc Natl Acad Sci, vol.109, issue.16, p.3341081, 2012.

F. Xiao, I. Fofana, L. Heydmann, H. Barth, E. Soulier et al., Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents, PLoS Pathog, vol.10, issue.5, p.4022730, 2014.

E. Steinmann, J. Doerrbecker, M. Friesland, N. Riebesehl, C. Ginkel et al., Characterization of hepatitis C virus intra-and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment, J Virol, vol.87, issue.24, p.24089562, 2013.

P. Central and P. , , p.3838269

K. G. Hadlock, R. E. Lanford, S. Perkins, J. Rowe, Q. Yang et al., Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes, J Virol, vol.74, issue.22, p.11044085, 2000.

M. Law, T. Maruyama, J. Lewis, E. Giang, A. W. Tarr et al., Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge, Nat Med, vol.14, issue.1, pp.25-32, 2008.

S. J. Merat, R. Molenkamp, K. Wagner, S. M. Koekkoek, D. Van-de-berg et al., Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance, PLoS One, vol.11, issue.10, p.5077102, 2016.

J. R. Bailey, A. I. Flyak, V. J. Cohen, H. Li, L. N. Wasilewski et al., Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance, JCI Insight, vol.2, issue.9, p.5414559, 2017.

C. H. Chan, K. G. Hadlock, S. K. Foung, and S. Levy, V(H)1-69 gene is preferentially used by hepatitis C virusassociated B cell lymphomas and by normal B cells responding to the E2 viral antigen, Blood, vol.97, issue.4, p.11159532, 2001.

N. Tzarum, E. Giang, L. Kong, L. He, J. Prentoe et al., Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies, Sci Adv, vol.5, issue.1, p.6314831, 2019.

S. Lang, J. Xie, X. Zhu, N. C. Wu, R. A. Lerner et al., Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem, Cell Rep, vol.20, issue.12, p.28930686, 2017.

P. Central and P. , , p.5679313

L. Kong, E. Giang, T. Nieusma, R. U. Kadam, K. E. Cogburn et al., Hepatitis C virus E2 envelope glycoprotein core structure, Science, vol.342, issue.6162, p.24288331, 2013.
DOI : 10.1126/science.1243876
URL : http://europepmc.org/articles/pmc3954638?pdf=render

J. Adolf-bryfogle, Q. Xu, B. North, A. Lehmann, and R. L. Dunbrack, PyIgClassify: a database of antibody CDR structural classifications, Nucleic Acids Res, vol.43, p.4383924, 2015.

J. Sui, W. C. Hwang, S. Perez, G. Wei, D. Aird et al., Structural and functional bases for broadspectrum neutralization of avian and human influenza A viruses, Nat Struct Mol Biol, vol.16, issue.3, p.2692245, 2009.

C. A. Thomson, S. Bryson, G. R. Mclean, A. L. Creagh, E. F. Pai et al., Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus, The EMBO journal, vol.27, p.2567409, 2008.

A. W. Tarr, A. M. Owsianka, D. Jayaraj, R. J. Brown, T. P. Hickling et al., Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33, J Gen Virol, vol.88, p.17947521, 2007.

P. Zhang, L. Zhong, E. B. Struble, H. Watanabe, A. Kachko et al., Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity, Proc Natl Acad Sci, vol.106, issue.18, p.2670884, 2009.

C. Kuiken, K. Yusim, L. Boykin, and R. Richardson, The Los Alamos hepatitis C sequence database. Bioinformatics, vol.21, pp.379-84, 2005.

E. Scarselli, H. Ansuini, R. Cerino, R. M. Roccasecca, S. Acali et al., The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus, Embo J, vol.21, issue.19, pp.5017-5042, 2002.

P. Central and P. , , p.129051

P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi et al., Binding of hepatitis C virus to CD81, Science, vol.282, issue.5390, p.9794763, 1998.

F. Douam, V. L. Dao-thi, G. Maurin, J. Fresquet, D. Mompelat et al., Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry, Hepatology, vol.59, issue.3, p.24038151, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01010615

R. Burioni, N. Mancini, S. Carletti, M. Perotti, A. Grieco et al., Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection, Virology, vol.327, issue.2, p.15351212, 2004.

Z. Y. Keck, A. Saha, J. Xia, Y. Wang, P. Lau et al., Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations, J Virol, vol.85, issue.20, p.3187491, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00630502

A. W. Tarr, P. Lafaye, L. Meredith, L. Damier-piolle, R. A. Urbanowicz et al., An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission, Hepatology, vol.58, issue.3, p.23553604, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01373206

R. Velazquez-moctezuma, A. Galli, M. Law, J. Bukh, and J. Prentoe, Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance, J Infect Dis, vol.219, issue.1, pp.68-79, 2019.

H. L. Tillmann, A. J. Thompson, K. Patel, M. Wiese, H. Tenckhoff et al., A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology, vol.139, p.20637200, 2010.

A. I. Flyak, S. Ruiz, M. D. Colbert, T. Luong, J. E. Crowe et al., HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design, Cell Host Microbe, vol.24, issue.5, p.6258177, 2018.

S. Teutsch, F. Luciani, N. Scheuer, L. Mccredie, P. Hosseiny et al., Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort, BMC Public Health, vol.10, issue.1, p.2975656, 2010.

S. T. Pham, R. A. Bull, J. M. Bennett, W. D. Rawlinson, G. J. Dore et al., Frequent multiple hepatitis C virus infections among injection drug users in a prison setting, Hepatology, vol.52, issue.5, p.21038409, 2010.

K. Katoh and D. M. Standley, MAFFT multiple sequence alignment software version 7: improvements in performance and usability, Mol Biol Evol, vol.30, issue.4, p.3603318, 2013.

B. Bartosch, J. Dubuisson, and F. L. Cosset, Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes, J Exp Med, vol.197, issue.5, p.12615904, 2003.
DOI : 10.1084/jem.20021756
URL : https://hal.archives-ouvertes.fr/inserm-00133783

T. H. Carlsen, J. Pedersen, J. C. Prentoe, E. Giang, Z. Y. Keck et al., Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a, Hepatology, vol.60, issue.5, p.25043937, 2014.

P. Central and P. , , p.4415877

J. M. Gottwein, T. K. Scheel, B. Callendret, Y. P. Li, H. B. Eccleston et al., Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies, J Virol, vol.84, issue.10, p.2863810, 2010.

R. Suzuki and H. Shimodaira, Pvclust: an R package for assessing the uncertainty in hierarchical clustering, Bioinformatics, vol.22, issue.12, pp.1540-1542, 2006.

E. Paradis, J. Claude, and K. Strimmer, APE: Analyses of Phylogenetics and Evolution in R language, Bioinformatics, vol.20, issue.2, pp.289-90, 2004.
URL : https://hal.archives-ouvertes.fr/ird-01887318

X. Brochet, M. P. Lefranc, V. Giudicelli, and . Imgt/v-, QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis, Nucleic Acids Res, vol.36, p.2447746, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00322389

T. Beaumont, S. Merat, C. J. Schinkel, R. Molenkamp, and B. V. Therapeutics, Hepatitis C virus specific antibody. US patent application 2017/0313764 A1, 2017.